Navigation Links
New System Devised To Guide Doctors Treating Patients With Symptomatic Myocardial Bridging
Date:7/1/2008

Symptoms, non-invasive tests, and heart flow tests combine to reduce subjective decision-making

Los Angeles (PRWEB) July 1, 2008 -- What type of intervention, if any, should cardiologists offer their patients who have a heart abnormality called myocardial bridging and symptoms of heart problems?

A research team at Cedars-Sinai Medical Center, the University of Texas Medical Branch and RWTH Aachen University in Germany has developed a new classification system that may help guide decision-making, according to Ernst R. Schwarz, M.D., Ph.D., a cardiologist at Cedars-Sinai's Heart Institute who is the first and corresponding author of an article in the June 25, 2008, online edition of Cardiology.

Myocardial bridging occurs when the heart is malformed, with a bridge of muscle fibers overlying a section of a coronary artery, usually the left anterior descending (LAD) artery. When the heart beats, the artery is squeezed and normal blood flow is disrupted during both the pumping and relaxed cycles. This may lead to signs and symptoms similar to those caused by coronary artery disease but which are primarily the result of the entrapment and constriction of this major artery.

Many patients have no symptoms and may be unaware that they have the malformation unless it is detected through diagnostic imaging. Although often considered a harmless normal variant, myocardial bridging has been linked to a variety of conditions, including heart rhythm abnormalities, heart attacks and even sudden cardiac death.

"From medication management to angioplasty and bypass surgery, there are a number of therapies available for patients who have myocardial bridging. But there has been no universally accepted protocol to determine whether a patient with myocardial bridging requires therapy, or which option is best in each case," said Schwarz. "Our study was designed to evaluate the usefulness of several diagnostic tests and to provide guidelines for doctors choosing the most appropriate treatments for their patients."

The retrospective study included 157 patients who had myocardial bridging (MB) and no evidence of other heart disease or coronary artery disease. This is believed to be the largest group of MB patients in the literature and - with a five-year follow-up - the longest observation period described in the medical literature. Another 100 patients without MB, artery disease or other heart disease made up a control group.

The researchers reviewed the patients' clinical histories for symptoms of typical angina (chest pain during stress with relief at rest); atypical angina (non-exertional chest pain); non-specific symptoms, such as palpitations and fatigue; or no symptoms. They evaluated results from non-invasive tests, such as EKGs,exercise stress tests or nuclear SPECT scans (Thallium 201 scintigraphy in single photon emission computer tomography), angiograms and invasive tests measuring different hemodynamic parameters using microtransducers within the arteries of the heart.

They found that clinical symptoms, EKGs and non-invasive stress tests are not specific for diagnosing myocardial bridging, but in patients who have myocardial bridging, clinical symptoms correlated with results from qualitative coronary angiography (QCA) and blood flow studies such as intracoronary Doppler and intravascular ultrasound.

Previous attempts to develop classification systems revolved around subjective criteria, such as the estimated percent of artery narrowing and/or the length of the compressed segment of artery.

"Classifications based on visual evaluation are subject to quantitative error and do not accurately assess arterial function. In our classification system, we incorporated clinical symptoms and results of both noninvasive and invasive diagnostic tests. Qualitative coronary angiography and intracoronary Doppler hemodynamics were able to assess the functional significance of myocardial bridging," Schwarz said.

The researchers placed the 157 MB patients into three categories:

  • 58 were in class A - Having clinical symptoms but no objective signs of ischemia.
  • 62 were in class B - Having clinical symptoms and objective signs of ischemia by non-invasive stress tests.
  • 37 were in class C - Having clinical symptoms and objective altered intracoronary hemodynamics, based on angiography and intracoronary Doppler - with or without signs of ischemia by noninvasive stress tests.

Based on initial observations and five-year follow-up, the cardiologists propose a new diagnostic work-up and therapeutic strategy:

Type A: No further diagnostic work or therapy is needed. Nitrates should be avoided. In rare cases, beta- blockers might be considered temporarily to relieve symptoms.

Type B: Initiate beta-blockers or calcium channel blockers. If symptoms are not relieved, quantitative coronary angioplasty or invasive blood-flow studies should be performed, after which stenting may be considered if there is objective evidence of reduced blood flow to the heart muscle.

Type C: Initiate beta-blockers or calcium channel blockers. If symptoms are refractory, consider stenting of the bridged segment.

"One of our most important recommendations is that Type C patients - those with hemodynamic changes - always be treated, regardless of results of non-invasive stress testing," Schwarz said, adding that the authors believe the new classification system will enable cardiologists worldwide to better risk -stratify
and treat patients with this frequent congenital coronary anomaly.

###


'/>"/>
Source: PRWeb
Copyright©2008 Vocus, Inc.
All rights reserved

Related medicine news :

1. Wound Management Technologies, Inc. Announces Sales Agreement with EWA Government Systems, Inc.
2. SPO Medical Launching Enhanced PulseOx 7500(TM) Oximetry System
3. WaferGens SmartChip(TM) Real-Time PCR System to Begin Alpha Testing at University of Pittsburgh Medical School
4. Tongue Drive system lets persons with disabilities operate powered wheelchairs, computers
5. European Ministers Sign Groundbreaking Charter on Health System
6. New system devised to guide doctors treating patients with symptomatic myocardial bridging
7. What price for a more effective health care system?
8. First CyberKnife System to be Installed in Canada
9. Impliant Restarts European Clinical Activities for Patented TOPS(TM) Spine System
10. StrionAir System A130 Air Purification Product Reduces Fan Energy by More Than 10 Percent
11. Pathway Medical Technologies Awarded New Patent for Pathway PV(TM) Atherectomy System for Improved Differential Cutting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... ... May 24, 2016 , ... Women's ... , Roberta Jordan is a Certified Nurse Midwife who was born and raised ... then went on to complete her masters degree from the University of Mexico. ...
(Date:5/24/2016)... ... 24, 2016 , ... Educational opportunities, and therefore life chances, ... communities providing richer opportunities. Recognizing the key role of housing in this system, ... school choice policies; (c) school desegregation policies; (d) wealth-focused policies; and (e) housing-focused ...
(Date:5/24/2016)... ... 24, 2016 , ... Regenerative Medicine is being transformed by ongoing research and ... protocols and patient results as have been achieved with Okyanos Cell Therapy ... of care for patients worldwide. , As the Medical Advisory Chairman at Okyanos, Eric ...
(Date:5/24/2016)... ... 2016 , ... Backed by decades of experience, Metroloji Okulu ... the best suited solution to meet regulatory requirements. Their professional staff also performs ... Istanbul. , Metroloji Okulu specializes in MadgeTech’s line of medical and pharmaceutical ...
(Date:5/24/2016)... ... May 24, 2016 , ... American Gene Technologies ... to its board of directors. Otterstatter is co-founder, president and CEO of ... technological innovations that lead to broad-based healthcare solutions. , “Jon knows how to ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... , May 24, 2016 ... beide primären Endpunkte und demonstriert ... in ‚ausgezeichneter plus guter , ...    ,      (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a ... heute neue positive Daten von der MORA-Studie der ...
(Date:5/24/2016)... LAWRENCE, Mass. , May 24, 2016  NxStage ... medical technology company focused on advancing renal care, today ... Officer, plans to participate in the following schedule of ... will be made available at http://ir.nxstage.com/ . ... Jefferies Healthcare Conference NY, NY           Friday, ...
(Date:5/24/2016)... , May 24, 2016 ... de doble terapia del mundo, introduce catéteres para ... OrbusNeich, una compañía global especializada en ... vidas, ha expandido su cartera incluyendo productos para ... JADE™ y Scoreflex™ PTA son los dispositivos de ...
Breaking Medicine Technology: